Recent SEC filings, including legal opinions on share issuance dated March 2026, underscore ongoing regulatory preparations for Encore Medical’s planned $15 million IPO of 3 million shares at an assumed $5 price, which would imply a post-offering market capitalization near $49 million. Persistent delays in final pricing and NYSE American listing—originally eyed for mid-May—have elevated trader consensus on the 82% probability of no IPO before June 2026, reflecting typical hurdles for small-cap medtech offerings such as FDA trial funding needs and market volatility. With the company still pre-U.S. commercial approval and reporting modest revenues, these factors reinforce the low odds assigned to the $45–55 million closing cap ranges while highlighting the binary risk tied to timely deal execution.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেডEncore Medical IPO Closing Market Cap
Encore Medical IPO Closing Market Cap
No IPO before June 2026 82%
45M–50M 6%
55M+ 4.0%
50M–55M 3.8%
$24,088 Vol.
$24,088 Vol.
Apr 22, 2026
<45M
2%
45M–50M
6%
50M–55M
4%
55M+
4%
No IPO before June 2026
82%
No IPO before June 2026 82%
45M–50M 6%
55M+ 4.0%
50M–55M 3.8%
$24,088 Vol.
$24,088 Vol.
Apr 22, 2026
<45M
$7,323 Vol.
2%
45M–50M
$2,625 Vol.
6%
50M–55M
$1,823 Vol.
4%
55M+
$3,121 Vol.
4%
No IPO before June 2026
$9,195 Vol.
82%
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent SEC filings, including legal opinions on share issuance dated March 2026, underscore ongoing regulatory preparations for Encore Medical’s planned $15 million IPO of 3 million shares at an assumed $5 price, which would imply a post-offering market capitalization near $49 million. Persistent delays in final pricing and NYSE American listing—originally eyed for mid-May—have elevated trader consensus on the 82% probability of no IPO before June 2026, reflecting typical hurdles for small-cap medtech offerings such as FDA trial funding needs and market volatility. With the company still pre-U.S. commercial approval and reporting modest revenues, these factors reinforce the low odds assigned to the $45–55 million closing cap ranges while highlighting the binary risk tied to timely deal execution.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
মার্কেট ওপেন হয়েছে: Apr 3, 2026, 7:59 PM ET
ভলিউম
$24,088শেষ তারিখ
Apr 22, 2026মার্কেট ওপেন হয়েছে
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Recent SEC filings, including legal opinions on share issuance dated March 2026, underscore ongoing regulatory preparations for Encore Medical’s planned $15 million IPO of 3 million shares at an assumed $5 price, which would imply a post-offering market capitalization near $49 million. Persistent delays in final pricing and NYSE American listing—originally eyed for mid-May—have elevated trader consensus on the 82% probability of no IPO before June 2026, reflecting typical hurdles for small-cap medtech offerings such as FDA trial funding needs and market volatility. With the company still pre-U.S. commercial approval and reporting modest revenues, these factors reinforce the low odds assigned to the $45–55 million closing cap ranges while highlighting the binary risk tied to timely deal execution.
This market will resolve based on Encore Medical’s market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 22 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
ভলিউম
$24,088শেষ তারিখ
Apr 22, 2026মার্কেট ওপেন হয়েছে
Apr 3, 2026, 7:59 PM ETResolver
0x69c47De9D...Recent SEC filings, including legal opinions on share issuance dated March 2026, underscore ongoing regulatory preparations for Encore Medical’s planned $15 million IPO of 3 million shares at an assumed $5 price, which would imply a post-offering market capitalization near $49 million. Persistent delays in final pricing and NYSE American listing—originally eyed for mid-May—have elevated trader consensus on the 82% probability of no IPO before June 2026, reflecting typical hurdles for small-cap medtech offerings such as FDA trial funding needs and market volatility. With the company still pre-U.S. commercial approval and reporting modest revenues, these factors reinforce the low odds assigned to the $45–55 million closing cap ranges while highlighting the binary risk tied to timely deal execution.
Polymarket ডেটা রেফারেন্স করে পরীক্ষামূলক AI-জেনারেটেড সারাংশ। এটি ট্রেডিং পরামর্শ নয় এবং এই মার্কেট কীভাবে রেজলভ হয় তাতে কোনো ভূমিকা রাখে না। · আপডেটেড
বাহ্যিক লিংক থেকে সাবধান।
বাহ্যিক লিংক থেকে সাবধান।
সচরাচর জিজ্ঞাসা